Elanco Animal Health Incorporated $ELAN Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 23.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,914,814 shares of the company’s stock after selling 1,216,302 shares during the period. Bank of New York Mellon Corp’s holdings in Elanco Animal Health were worth $88,592,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State of Michigan Retirement System acquired a new position in Elanco Animal Health during the third quarter worth about $2,383,000. Teachers Retirement System of The State of Kentucky acquired a new position in Elanco Animal Health during the third quarter worth about $2,215,000. JPMorgan Chase & Co. raised its position in Elanco Animal Health by 266.4% during the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after acquiring an additional 1,394,839 shares during the last quarter. Royce & Associates LP raised its position in Elanco Animal Health by 21.3% during the third quarter. Royce & Associates LP now owns 602,564 shares of the company’s stock worth $12,136,000 after acquiring an additional 105,632 shares during the last quarter. Finally, Ameritas Investment Partners Inc. acquired a new position in Elanco Animal Health during the third quarter worth about $1,876,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $23.67 on Tuesday. Elanco Animal Health Incorporated has a one year low of $13.15 and a one year high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a 50 day moving average price of $22.86 and a 200 day moving average price of $23.42. The firm has a market capitalization of $11.82 billion, a price-to-earnings ratio of -47.34, a price-to-earnings-growth ratio of 1.55 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the prior year, the business posted $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ELAN shares. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Leerink Partners boosted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.